Wyeth's transdermal nitroglycerin
Executive Summary
FDA conditionally approved Wyeth's transdermal delivery system, trademarked Deponit 5 and Deponit 10, May 6. The product is available in dosages of 5 mg/24 hours and 10 mg/24 hours. Wyeth is the fifth firm to enter the transdermal nitroglycerin market. Bolar, Ciba-Geigy, Searle and Key Pharmaceuticals already market transdermal nitroglycerin.